EP3645050A4 - MULTI-SPECIFIC ANTIBODIES AND ASSOCIATED PRODUCTION AND USE PROCESSES - Google Patents

MULTI-SPECIFIC ANTIBODIES AND ASSOCIATED PRODUCTION AND USE PROCESSES Download PDF

Info

Publication number
EP3645050A4
EP3645050A4 EP18825382.7A EP18825382A EP3645050A4 EP 3645050 A4 EP3645050 A4 EP 3645050A4 EP 18825382 A EP18825382 A EP 18825382A EP 3645050 A4 EP3645050 A4 EP 3645050A4
Authority
EP
European Patent Office
Prior art keywords
specific antibodies
use processes
associated production
production
processes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18825382.7A
Other languages
German (de)
French (fr)
Other versions
EP3645050A2 (en
Inventor
Yi Zhu
Ole Olsen
Dong Xia
David JELLYMAN
Katrina BYKOVA
Anne-Marie Rousseau
Bill Brady
Blair RENSHAW
Brian Kovacevich
Yu Liang
Zeren Gao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Systimmune Inc
Original Assignee
Sichuan Baili Pharmaceutical Co Ltd
Systimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Baili Pharmaceutical Co Ltd, Systimmune Inc filed Critical Sichuan Baili Pharmaceutical Co Ltd
Publication of EP3645050A2 publication Critical patent/EP3645050A2/en
Publication of EP3645050A4 publication Critical patent/EP3645050A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP18825382.7A 2017-06-25 2018-06-22 MULTI-SPECIFIC ANTIBODIES AND ASSOCIATED PRODUCTION AND USE PROCESSES Pending EP3645050A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762524554P 2017-06-25 2017-06-25
PCT/US2018/039153 WO2019005637A2 (en) 2017-06-25 2018-06-22 Multi-specific antibodies and methods of making and using thereof

Publications (2)

Publication Number Publication Date
EP3645050A2 EP3645050A2 (en) 2020-05-06
EP3645050A4 true EP3645050A4 (en) 2021-08-11

Family

ID=64742648

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18825382.7A Pending EP3645050A4 (en) 2017-06-25 2018-06-22 MULTI-SPECIFIC ANTIBODIES AND ASSOCIATED PRODUCTION AND USE PROCESSES

Country Status (5)

Country Link
US (1) US11649286B2 (en)
EP (1) EP3645050A4 (en)
JP (1) JP7356970B2 (en)
CN (1) CN111148761B (en)
WO (1) WO2019005637A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190248A1 (en) 2017-04-21 2019-10-20 Amgen Inc Trem2 antigen binding proteins and uses thereof
TW201904588A (en) * 2017-06-25 2019-02-01 美商西雅圖免疫公司 Guidance and navigation control protein manufacturing and use methods
US11535667B2 (en) * 2017-08-28 2022-12-27 Systimmune, Inc. Anti-CD3 antibodies and methods of making and using thereof
WO2019166650A1 (en) * 2018-03-02 2019-09-06 Cdr-Life Ag Trispecific antigen binding proteins
EP4097131A1 (en) * 2020-01-29 2022-12-07 Merus N.V. Means and method for modulating immune cell engaging effects
TWI888487B (en) * 2020-02-14 2025-07-01 日商協和麒麟股份有限公司 Bispecific antibodies that bind to CD3
GB202002581D0 (en) 2020-02-24 2020-04-08 Gammadelta Therapeutics Ltd Novel antibodies
ES2943063T5 (en) 2020-08-14 2026-05-05 Gammadelta Therapeutics Ltd Multispecific anti-tcr delta variable 1 antibodies
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
US11919958B2 (en) 2020-08-19 2024-03-05 Xencor, Inc. Anti-CD28 compositions
WO2022094299A2 (en) * 2020-10-30 2022-05-05 Janux Therapeutics, Inc. Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof
KR20230160253A (en) 2021-02-17 2023-11-23 감마델타 테라퓨틱스 엘티디 anti-TCR delta variable 1 antibody
US20250074996A1 (en) * 2021-02-19 2025-03-06 Innovent Biologics (Suzhou) Co., Ltd. ANTI-GPRC5DxBCMAxCD3 TRISPECIFIC ANTIBODY AND USE THEREOF
CN114853897B (en) * 2021-04-15 2024-01-26 北京大学深圳研究生院 Anti-CD19/CD22/CD3 trispecific antibodies and their uses
AU2022260298A1 (en) * 2021-04-23 2023-11-02 Shanghai Henlius Biotech, Inc. Anti-gpc3 antibodies, multispecific antibodies and methods of use
EP4384218A4 (en) * 2021-08-09 2025-11-05 Merck Patent Gmbh PROTEINS TO DECOUPLE T-CELL-MEDIATED TUMORCYTOTOXICITY FROM THE RELEASE OF PROINFLAMMATORY CYTOKINES
IL314993A (en) 2022-02-23 2024-10-01 Xencor Inc Anti-CD28 X anti-PSMA antibodies
CN115305237B (en) * 2022-07-08 2023-07-14 中南大学 A method for the expansion and large-scale production of optimized regulatory T cells
US20240294651A1 (en) 2023-01-30 2024-09-05 Kymab Limited Antibodies
TW202436358A (en) * 2023-03-01 2024-09-16 大陸商江蘇恆瑞醫藥股份有限公司 Fap/4-1bb/cd40 binding molecules and pharmaceutical uses thereof
WO2025016012A1 (en) * 2023-07-14 2025-01-23 Genor Biopharma Co., Ltd. Anti-PD-1/CTLA-4/TIGIT TRISPECIFIC ANTIBODIES AND USE THEREOF
WO2025059589A1 (en) * 2023-09-13 2025-03-20 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Immune cell engaging molecules
WO2026052000A1 (en) * 2024-09-04 2026-03-12 上海迈晋生物医药科技有限公司 Pharmaceutical composition containing fap/4-1bb/cd40 binding molecule, and use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010028796A1 (en) * 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Trispecific hexavalent antibodies
EP2789630A1 (en) * 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
WO2015013671A1 (en) * 2013-07-25 2015-01-29 Cytomx Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
WO2016173605A1 (en) * 2015-04-29 2016-11-03 Institute For Research In Biomedicine Ultra-potent neutralization of cytokines by multispecific antibodies and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4754219B2 (en) * 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド Antibodies directed against tumor necrosis factor and their use
US9783601B2 (en) * 2010-12-01 2017-10-10 Alderbio Holdings Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
GB201020995D0 (en) * 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
HK1217023A1 (en) * 2013-05-28 2016-12-16 Numab Innovation Ag Novel antibodies
CA2955947A1 (en) * 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
EP3204415B1 (en) * 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1
US10428155B2 (en) * 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
US20180340025A1 (en) * 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
JP6932700B2 (en) * 2015-09-15 2021-09-08 アムジエン・インコーポレーテツド Tetravalent bispecific antigen-binding proteins and tetravalent quadrispecific antigen-binding proteins, and their use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010028796A1 (en) * 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Trispecific hexavalent antibodies
EP2789630A1 (en) * 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
WO2015013671A1 (en) * 2013-07-25 2015-01-29 Cytomx Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
WO2016173605A1 (en) * 2015-04-29 2016-11-03 Institute For Research In Biomedicine Ultra-potent neutralization of cytokines by multispecific antibodies and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BATLEVI CONNIE LEE ET AL: "Novel immunotherapies in lymphoid malignancies", NATURE REVIEWS CLINICAL ONCOLOGY, NATURE, NY, US, vol. 13, no. 1, 3 November 2015 (2015-11-03), pages 25 - 40, XP037134828, ISSN: 1759-4774, [retrieved on 20151103], DOI: 10.1038/NRCLINONC.2015.187 *
BURGER JAN A ET AL: "The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapies", SEMINARS IN CANCER BIOLOGY, SAUNDERS SCIENTIFIC PUBLICATIONS, PHILADELPHIA, PA, US, vol. 24, 7 September 2013 (2013-09-07), pages 71 - 81, XP028815015, ISSN: 1044-579X, DOI: 10.1016/J.SEMCANCER.2013.08.011 *
S. OSTRAND-ROSENBERG ET AL: "The Programmed Death-1 Immune-Suppressive Pathway: Barrier to Antitumor Immunity", THE JOURNAL OF IMMUNOLOGY, vol. 193, no. 8, 3 October 2014 (2014-10-03), US, pages 3835 - 3841, XP055257410, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1401572 *
See also references of WO2019005637A2 *

Also Published As

Publication number Publication date
WO2019005637A3 (en) 2020-03-26
EP3645050A2 (en) 2020-05-06
CN111148761B (en) 2024-02-13
WO2019005637A2 (en) 2019-01-03
US20230322920A1 (en) 2023-10-12
JP2020529864A (en) 2020-10-15
CN111148761A (en) 2020-05-12
JP7356970B2 (en) 2023-10-05
US11649286B2 (en) 2023-05-16
US20200157213A1 (en) 2020-05-21

Similar Documents

Publication Publication Date Title
MA46529A (en) ANTI-LAG-3 ANTIBODIES AND PROCESSES FOR USE
EP3684821A4 (en) ANTI-HLA-A2 ANTIBODIES AND PROCESSES FOR USE
MA50948A (en) ANTIBODIES AND METHODS OF USING THE SAME
EP3645048A4 (en) MULTISPECIFIC ANTIBODIES AND ASSOCIATED MANUFACTURING AND USE PROCESSES
MA47691A (en) ANTI-CD33 ANTIBODIES AND PROCESSES FOR USE
MA49950A (en) ANTI-B7-H4 ANTIBODIES AND PROCEDURES FOR USE
MA42971A (en) ANTI-PDL1 ANTIBODIES, ACTIVABLE ANTI-PLD1 ANTIBODIES, AND METHODS OF USE THEREOF
MA50949A (en) ANTI-CTLA-4 ANTIBODIES AND PROCESSES FOR USE
MA43389A (en) ANTI-OX40 ANTIBODIES AND PROCESSES FOR USE
EP3706784A4 (en) COMPOSITIONS AND PROCESSES FOR THE PRODUCTION OF T LYMPHOCYTES
MA43018A (en) ANTI-PD1 ANTIBODIES AND METHODS OF USE
MA50359A (en) ANTI-CD38 ANTIBODIES AND METHODS OF USE
MA46770A (en) ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE
EP3307321A4 (en) MULTI-SPECIFIC ANTIBODY PLATFORM AND ASSOCIATED METHODS
EP3645741A4 (en) ANTI-4-1BB ANTIBODIES AND THEIR PREPARATION AND USE PROCESSES
MA42447A (en) ANTI-PD-1 ANTIBODIES, ACTIVABLE ANTI-PD-1 ANTIBODIES, AND METHODS OF USE THEREOF
MA42979A (en) ANTI-AGING ANTIBODIES AND RELATED METHODS OF USE
MA42043A (en) ANTI-OX40 ANTIBODIES AND METHODS OF USE THEREOF
EP3472200A4 (en) ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE THEREOF
MA43365A (en) ANTI-DR5 ANTIBODIES AND METHODS FOR USING THE SAME
MA43802A (en) CELLULOSIC MATERIALS AND METHODS FOR THE MANUFACTURE AND USE OF THE SAME
MA50569A (en) FILLING-FINISHING UNITS AND ASSOCIATED PROCESSES
EP3414266A4 (en) WIDESPREAD NEUTRALIZING ANTIBODIES AGAINST HIV-1 AND USES THEREOF
EP3491025A4 (en) FCRN ANTIBODIES AND METHODS OF USE
EP3645049A4 (en) MULTISPECIFIC ANTIBODIES AND ASSOCIATED PREPARATION AND USE PROCESSES

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191217

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/68 20170101AFI20210331BHEP

Ipc: C07K 16/30 20060101ALI20210331BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20210714

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/68 20170101AFI20210708BHEP

Ipc: C07K 16/30 20060101ALI20210708BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD.

Owner name: SYSTIMMUNE, INC.

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230518

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD.

Owner name: SYSTIMMUNE, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20231108

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SYSTIMMUNE, INC.